Semaglutide intranasal (Mattern Pharmaceuticals)

司美格鲁肽鼻喷制剂 (Mattern Pharmaceuticals)

Report date: 2024/06/07 10:20:43

Base Information

Drug NameSemaglutide intranasal (Mattern Pharmaceuticals)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySwitzerland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMetp Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesMetp Pharma Ag
Inactive CompaniesN/A
Active IndicationsObesity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A